TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22057498
Drug: HPPH-PDT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPPH-PDT with 4 mg/m2 HPPH (light dose at 24 hours)
Study: 18958483
Drug: Amniotomy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amniotomy and immediate oxytocin infusion
Study: 18958483
Drug: Amniotomy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amniotomy and delayed oxytocin infusion
Study: 16775166
Drug: History of
Normalized name: BEMOTRIZINOL 0.8 mL in 100 mL / OCTINOXATE 7 mL in 100 mL TOPICAL CREAM [THE HISTORY OF WHOO GONG JIN HYANG HAE YOON SUN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: History of injecting drug use
Study: 1101820
Drug: Topical polyinosinic
Normalized name: polyinosinic-polycytidilic acid (Poly-ICLC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical polyinosinic acid-polycytidylic acid [poly(I:C)]
Study: 15198873
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin at a target dose of 14 microg/kg/h
Study: 18494791
Drug: 200 mg/day
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/day TPM
Study: 16813180
Drug: Consciousness‐restoring resuscitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consciousness‐restoring resuscitation acupuncture (treatment group)
Study: 16813180
Drug: Chinese medicine
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine (control group)
Study: 12673081
Drug: KC 2%
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: KC 2% foaming gel
Study: 12673081
Drug: CIC 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIC 1% cream
Study: 1599264
Drug: 17 mg/mL
Normalized name: menthol 17 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 mg/mL cyclosporine
Study: 1599264
Drug: 10 mg/mL
Normalized name: urea 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/mL cyclosporine
Study: 1599264
Drug: 2.5 mg/mL
Normalized name: iodine 2.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg/mL cyclosporine
Study: 6202408
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of bleomycin
Study: 6202408
Drug: Intermittent bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent bolus injection of bleomycin
Study: 30717805
Drug: Liberal transfusion
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal transfusion strategy (transfusion of a single RBC unit when Hb ≤ 9 g/dl with a target range for post-transfusion Hb level of 9-10.5 g/dl)
Study: 25265986
Drug: 3% Rumex
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% Rumex occidentalis cream
Study: 25265986
Drug: 4% Hydroquinone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% Hydroquinone cream
Study: 20380479
Drug: Ketoprofen syrup
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoprofen syrup 0.5 mg/kg
Study: 20380479
Drug: Ibuprofen suspension
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen suspension 5 mg/kg
Study: 16115978
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (Mg) 2.48 mmol
Study: 24910102
Drug: Ketamine 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.2 mg/kg
Study: 12353197
Drug: Valacyclovir 250
Normalized name: valacyclovir 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir 250 mg (9.4‐13.3 mg/kg) twice daily
Study: 12353197
Drug: Valacyclovir 500
Normalized name: valacyclovir 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir 500 mg (13.2‐21.7 mg/kg) 3 times a day
Study: 31800752
Drug: Surgical Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical Therapy (ST)
Study: 31800752
Drug: Nonsurgical Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsurgical Therapy (NST)
Study: 17623467
Drug: BMS-378806 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS-378806 (100 to 1600 mg single oral dose)
Study: 17623467
Drug: BMS-378806 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS-378806 (100 to 1200 mg)
Study: 17623467
Drug: BMS-378806 (1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS-378806 (1600 mg)
Study: 15530201
Drug: Daily typed
Normalized name: turpentine / white spirit type 1 Topical Solution [Cornucrescine Daily Hoof Barrier]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily typed journal group
Study: 10599182
Drug: Nadolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol (80 mg)
Study: 29252047
Drug: Beetroot juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beetroot juice (BR; 140 ml/day, ∼800 mg/day nitrate)
Study: 23413606
Drug: Novel radioisotope
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel radioisotope therapies
Study: 31680143
Drug: Cytotoxic agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytotoxic agents
Study: 21353117
Drug: New generic
Approvals — FDA: no, EMA: no, PMDA: no
Description: New generic formulation of bicalutamide 50-mg tablets (test)
Study: 21353117
Drug: Currently marketed
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Currently marketed formulation of bicalutamide 50-mg tablets (reference)
Study: 17309908
Drug: Gentamicin 2
Normalized name: gentamicin 2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin 2 mg/kg, rifampicin 600 mg, vancomycin 15 mg/kg (with three further doses of 7.5 mg/kg at 12-hour intervals)
Study: 17309908
Drug: Cefuroxime 1.5
Normalized name: cefuroxime 1.5 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime 1.5 g at induction and three further doses of 750 mg at 8-hour intervals
Study: 12925049
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of ANP (0.25 microg/kg/min in 0.9% NaCl) after 3 weeks' pre‐treatment with placebo
Study: 10840536
Drug: Tropisetron 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron 0.1 mg/kg body weight
Study: 24489014
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg ORM-12741
Study: 24489014
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg ORM-12741
Study: 22828645
Drug: Hib-MenC-TT booster
Normalized name: TT 173
DrugBank: TT 173 (DB17717)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hib-MenC-TT booster dose
Study: 9888118
Drug: Weekly contingent
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly contingent condition (three negative test results required for the first take-home privilege)
Study: 8665128
Drug: Zamifenacin 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zamifenacin 30 mg
Study: 6099050
Drug: 5-fluorouracil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil at 200 mg/day combined with gestagen at 50 mg/day
Study: 6099050
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose estrogen (hexestrol at 60 mg/day)
Study: 6099050
Drug: 5-fluorouracil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil at 200 mg/day combined with hexestrol at 30 mg/day
Study: 6099050
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose estrogen (hexestrol at 60 mg/day) in patients already well controlled
Study: 27339107
Drug: 16% carbohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16% carbohydrate solution (CHO)
Study: 22929967
Drug: Microneedle treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microneedle treatment + daily topical application of diclofenac sodium
Study: 11814510
Drug: Surgical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical therapy for prolapse
Study: 31070463
Drug: Ropivacaine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine with clonidine 2 μg/kg
Study: 31070463
Drug: Ropivacaine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine and a subcutaneous injection of clonidine 2 μg/kg (SC clonidine)
Study: 28403589
Drug: Palmitoylethanolamide 300
Normalized name: Palmitoylethanolamide
DrugBank: Palmidrol (DB14043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palmitoylethanolamide 300 mg plus Alpha‐lipoic acid 300 mg (Peanase®)
Study: 28403589
Drug: Serenoa Repens
Normalized name: Serenoa Repens Fruit
DrugBank: Saw palmetto (DB14360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serenoa Repens at 320 mg
Study: 25456116
Drug: Dexmedetomidine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine infusion (0.5 μg · kg(‐1) initial dose followed by 0.4 μg · kg(‐1) h(‐1))
Study: 25456116
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline infusion (NS group)
Study: 30638863
Drug: VIS410 4000
Normalized name: IMMUNOGLOBULIN G1, ANTI-(INFLUENZA HEMAGGLUTININ) (HUMAN MONOCLONAL VIS410 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL VIS410 .KAPPA.-CHAIN, DIMER
Approvals — FDA: no, EMA: no, PMDA: no
Description: VIS410 4000 mg
Study: 30638863
Drug: VIS410 2000
Normalized name: IMMUNOGLOBULIN G1, ANTI-(INFLUENZA HEMAGGLUTININ) (HUMAN MONOCLONAL VIS410 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL VIS410 .KAPPA.-CHAIN, DIMER
Approvals — FDA: no, EMA: no, PMDA: no
Description: VIS410 2000 mg
Study: 30073693
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose cyclosporine A
Study: 16140544
Drug: sublingual piroxicam‐FDDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: sublingual piroxicam‐FDDF 20 mg/day
Study: 16140544
Drug: oral azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral azithromycin 500 mg/day
Study: 16140544
Drug: piroxicam‐FDDF 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: piroxicam‐FDDF 20 mg/day plus azithromycin 500 mg/day
Study: 16140544
Drug: piroxicam‐FDDF 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: piroxicam‐FDDF 20 mg/day
Study: 16140544
Drug: azithromycin 500
Normalized name: azithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: azithromycin 500 mg/day
Study: 12047415
Drug: BMS‐284756 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS‐284756 100 mg
Study: 12047415
Drug: BMS‐284756 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS‐284756 200 mg
Study: 12047415
Drug: BMS‐284756 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS‐284756 800 mg
Study: 12047415
Drug: BMS‐284756 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS‐284756 1200 mg
Study: 12047415
Drug: BMS‐284756 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS‐284756 (all doses)
Study: 7603807
Drug: Intravenous dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous dexamethasone (DXM)
Study: 7603807
Drug: Neither treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neither treatment (Control)
Study: 20555371
Drug: Sodium citrate
Normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium citrate (CIT) 0.5 g.kg‐1 body mass
Study: 17576847
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg flucloxacillin
Study: 10204902
Drug: 2 mL
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL of 2% mepivacaine
Study: 10204902
Drug: 4 mL
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mL of 2% mepivacaine
Study: 10204902
Drug: 6 mL
Normalized name: ethanol 0.6 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mL of 2% mepivacaine
Study: 21448197
Drug: Darbepoetin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darbepoetin (10 μg kg(‐1) subcutaneously)
Study: 11553000
Drug: G‐CSF‐mobilized peripheral
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF‐mobilized peripheral blood stem cell (PBSC) grafts
Study: 9692813
Drug: G‐CSF mobilization
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF mobilization
Study: 26523993
Drug: Aliskiren 300
Normalized name: aliskiren 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren 300 mg daily for 104 weeks
Study: 18490229
Drug: Preterax (perindopril
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preterax (perindopril 2 mg and indapamide 0.625 mg)
Study: 19789415
Drug: Cilazapril (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril (2.5 mg)
Study: 8136096
Drug: Continue HDFP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continue HDFP medication
Study: 8136096
Drug: Withdrawn from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawn from both diuretic plus reserpine
Study: 28301614
Drug: HP/TAZ lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: HP/TAZ lotion
Study: 29328639
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid + aminocaproic acid (2 mL)
Study: 21115926
Drug: Carboplatin (CBDCA)
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin (CBDCA) AUC 3 and Paclitaxel (PTX) 90 mg/m² (PCb arm)
Study: 21115926
Drug: Carboplatin (CBDCA)
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin (CBDCA) AUC 3 plus Gemcitabine (GEM) 1000 mg/m² (GCb arm)
Study: 10450387
Drug: Multipurpose disinfecting
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multipurpose disinfecting solution
Study: 7480237
Drug: Azithromycin (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (single oral dose taken at 8 P.M. the day before surgery)
Study: 2507125
Drug: LC9018 with
Approvals — FDA: no, EMA: no, PMDA: no
Description: LC9018 with radiation therapy
Study: 23588866
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural infusion (SEI)
Study: 11523612
Drug: Intravenous dofetilide
Normalized name: Dofetilide
DrugBank: Dofetilide (DB00204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous dofetilide
Study: 2738584
Drug: Intradermal hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal hepatitis B vaccine
Study: 9534677
Drug: Intramuscular hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular hepatitis B vaccine
Study: 2399180
Drug: Diazepam (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (0.6 mg/kg)
Study: 11701431
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg testosterone enanthate
Study: 11701431
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg testosterone enanthate
Study: 11701431
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg testosterone enanthate
Study: 18639360
Drug: Dose Matched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose Matched Therapeutic Exercises (DMTE)
Study: 11739462
Drug: E2 supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2 supplementation (1 mg micronized 17 beta‐E2 orally twice daily for 6‐23 days)
Study: 19554657
Drug: Sodium phosphate
Normalized name: Sodium Phosphate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium phosphate plus 240 mg of tablet simethicone
Study: 15586301
Drug: Mepivacaine 4%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepivacaine 4% with 0.1 mg of morphine
Study: 2979673
Drug: Pirenzepine 100
Normalized name: pirenzepine
DrugBank: Pirenzepine (DB00670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine 100 mg
Study: 2979673
Drug: Propantheline 15
Normalized name: propantheline 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propantheline 15 mg
Study: 2979673
Drug: Propantheline 45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propantheline 45 mg
Study: 23686894
Drug: Vaccinium arctostaphylos
Normalized name: Arctostaphylos tomentosa whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccinium arctostaphylos fruit hydroalcoholic extract (350 mg capsule every 8 hours for 2 months)
Study: 20019589
Drug: Clopidogrel Leti
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel Leti 75 mg
Study: 20019589
Drug: Clopidogrel Sanofi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel Sanofi (Plavix) 75 mg
Study: 11875324
Drug: Amiloride 2.5
Normalized name: amiloride 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride 2.5 + Hydrochlorothiazide 5 mg
Study: 6573315
Drug: Cefotetan 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotetan 0.5 g
Study: 6573315
Drug: Cefotetan 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotetan 1.0 g
Study: 695661
Drug: Prophylactic gestagen
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic gestagen therapy in the immediate post-ovulatory phase
Study: 23482914
Drug: 100 kVp
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 kVp setting and 370 mgI/mL contrast medium
Study: 23482914
Drug: 100 kVp
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 kVp setting and 300 mgI/mL contrast medium
Study: 23482914
Drug: 120 kVp
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 kVp setting and 370 mgI/mL contrast medium
Study: 19153029
Drug: Yunnan Baiyao
Normalized name: CAMPHOR (SYNTHETIC) 40.74 mg / MENTHOL 51.84 mg / METHYL SALICYLATE 117.998 mg TOPICAL PATCH [Yunnan Baiyao Pain Relieving]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yunnan Baiyao capsules
Study: 8006280
Drug: 50 mg/day
Normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/day of aspirin for 8 days
Study: 8006280
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not treated with aspirin)
Study: 8006280
Drug: Very low
Normalized name: Very low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very low dose aspirin therapy during pacing
Study: 25664701
Drug: Immediately loaded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediately loaded implants (test group)
Study: 25664701
Drug: Delayed loaded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed loaded implants (control group)
Study: 21862415
Drug: Eribulin mesylate
Normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eribulin mesylate (1.4 mg/m²) administered on days 1 and 8 of a 21-day cycle.
Study: 21862415
Drug: Eribulin mesylate
Normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eribulin mesylate (1.4 mg/m²) administered on days 1, 8, and 15 of a 28-day cycle.
Study: 14646651
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 8 mg IV dexamethasone 1 hour before the operation
Study: 14646651
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 8 mg IV dexamethasone at the beginning of the operation
Study: 14646651
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of 8 mg IV dexamethasone 1 hour before the operation, and 24 and 48 hours after the operation
Study: 14646651
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of 8 mg IV dexamethasone at the beginning of the operation, and 24 and 48 hours after the operation
Study: 14646651
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of 8 mg IV dexamethasone immediately after the operation, and 24 and 48 hours after the operation
Study: 14646651
Drug: Control, no
Normalized name: Ascensia Autodisc Control, Normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control, no dexamethasone administration before or after the operation
Study: 1955549
Drug: Control (natural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (natural intercourse after clomiphene treatment)
Study: 24401721
Drug: Coupled plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coupled plasma filtration adsorption (CPFA) with dose >0.18 L/kg/day
Study: 17350481
Drug: Allopurinol (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (300 mg/day, titrated to 100 mg TDS)
Study: 15732035
Drug: Combination mycophenolate
Normalized name: mycophenolate
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combination mycophenolate mofetil and prednisone (MMF-P)
Study: 10561297
Drug: Paclitaxel 200
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 200 mg/m² IV over 3 hours for eight cycles (24 weeks)
Study: 10561297
Drug: CMFP combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMFP combination chemotherapy (cyclophosphamide 100 mg/m²/d orally on days 1 to 14, methotrexate 40 mg/m² IV on days 1 and 8, fluorouracil 600 mg/m² IV on days 1 and 8, and prednisone 40 mg/m²/d orally on days 1 to 14) for six cycles (24 weeks)
Study: 8702043
Drug: Chloroquine (CQ)
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine (CQ) antimalarial treatment and chemoprophylaxis
Study: 8702043
Drug: Mefloquine (MQ)
DrugBank: Mefloquine (DB00358)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mefloquine (MQ) antimalarial treatment and chemoprophylaxis
Study: 8702043
Drug: Chloroquine (CQ)
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine (CQ) and Mefloquine (MQ) antimalarial treatment and chemoprophylaxis
Study: 31399071
Drug: Community mental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community mental health treatment and HIV counseling and testing